** Shares of Telix Pharmaceuticals rise 2.3% to a record high of A$26.46
** The biopharma co says its Illuccix, a prostate cancer imaging agent, received European approval
** Says all 18 European Economic Area member states agreed Illuccix should be approved
** Co stock on track for a fifth consecutive session of gains, if current trend holds
** Stock up over 7% YTD including session's moves
(Reporting by Rajasik Mukherjee in Bengaluru)
((Rajasik.Mukherjee@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。